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Abstract
Background: Little is currently known of the pathophysiological mechanisms triggering Charcot arthropathy
and regulating its recovery although foot trauma has been proposed as a major initiating factor by activation
of proinflammatory cytokines leading to increased osteoclastogenic activity and progressive bone destruction.
Several members of the IL-17 family of proinflammatory cytokines have been shown to play a key role in the
pathogenesis of inflammatory conditions affecting bone and joints but none has previously been studied in
Charcot foot patients. The aim of this study was to investigate the role of IL-17A, IL-17E and IL-17F in
patients presenting with Charcot foot.
Methods: Twenty-six consecutive Charcot patients were monitored during 2 years by repeated foot radiographs, MRI
and circulating levels of IL-17A, IL-17E and IL-17F. Analysis of cytokines was done by ultra-sensitive chemiluminescence
technique and data were analyzed by one-way repeated measures ANOVA. Neuropathic diabetic patients (n = 20) and
healthy subjects (n = 20) served as controls.
Results: Plasma IL-17A and IL-17E in weight-bearing Charcot patients at diagnosis were at the level of diabetic
controls, whereas IL-17F was significantly lower than diabetic controls. A significant increase in IL-17A and IL-17E
reaching a peak 2–4 months after inclusion and start of offloading treatment in Charcot patients was followed by
a gradual decrease to the level of diabetic controls at 2 years postinclusion. In contrast, IL-17F increased gradually
from inclusion to a level not significantly different from diabetic controls after 2 years.
Conclusions: Charcot patients display a significant elevation of all three IL-17 cytokines during the follow-up
period relative values at diagnosis and values in control patients supporting a role in the bone repair and remodeling
activity during the recovery phase. The rapid increase of IL-17A and IL-17E shortly after initiating off-loading treatment
could suggest this to be a response to immobilization and stabilization of the diseased foot.
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Background
The Charcot foot or Charcot arthropathy is a complex
and potentially limb-threatening, destructive process often
recognized by early signs such as pain, warmth, edema, or
pathologic fractures in a neuropathic foot [1]. We cur-
rently know little of the pathophysiology of Charcot other
than that it involves multiple background factors such as
peripheral neuropathy, with its secondary effects on circu-
lation, sensory input and foot biomechanics, and in most
cases diabetes. The triggering mechanism(s) remain how-
ever elusive although trauma has been proposed as one
such factor. The conjunction of these background factors
has been proposed to explain the association of features
that are typical of this disorder, namely osteolysis and vas-
cular calcification in association with intact lower limb
blood flow [2]. However, the acute Charcot foot is also
characterized by a pronounced inflammatory reaction, the
pathogenic significance of which has been the focus of
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several review articles in recent years [2, 3]. In an early
review [4], the author proposed that an initial trauma
could set off an inflammatory cascade resulting in in-
creased osteoclastogenesis due to disturbance in the
balance between RANKL and OPG. The role of the
RANKL/OPG-pathway was investigated in a recent
study showing that at diagnosis and onward, this path-
way is primarily involved in bone remodeling whereas
the powerful bone anabolic Wnt/β-catenin pathway,
which had not been previously investigated in Charcot
arthropathy patients, plays a critical role in remodeling
as well as preservation of the foot skeleton in the acute
and chronic phases of the disease [5].
Despite decade-long dominant role assigned to the
proinflammatory cytokines belonging to the T-helper 1
and T-helper 2 cell (Th1/Th2) subsets of the immune
system (e.g. IL-6, IL-1β and TNF-α) as the driving force
for the development and maintenance of inflammation-
driven bone- and joint diseases [6], it is now evident that
Th1/Th2 cannot alone account for the pathogenesis of
these disorders [7] and that many inflammatory condi-
tions are partly or largely driven by a new subset, namely
the T-helper 17 (Th17) cells [8], which are the main
source of IL-17 cytokines. This family is composed of six
members ranging from IL-17A to IL-17F which exert
their biological actions through activation of several cas-
cade systems, such as NFκB and kinase signaling path-
ways [9]. A growing number of studies in animals and
humans have shown IL-17A to be pivotal in a multitude
of bone-destructive processes, either by directly or in-
directly stimulating osteoclastogenesis [10] or by syner-
gizing with other proinflammatory cytokines, such as
TNF-α and IL-1β, in their bone destructive role [10].
Recent studies have shown that, despite being related,
these cytokines have differential, non-overlapping and
sometimes opposing effects [11, 12]. Despite Charcot ar-
thropathy being a bone degenerative condition, we are not
aware of any study investigating the role of this important
family of proinflammatory cytokines in Charcot patients.
This longitudinal observational study was designed to
explore the role of IL-17A, IL-17E and IL-17F in the
pathophysiology of Charcot arthropathy by measuring
plasma levels of the cytokines at presentation and re-
peatedly during 2 years until full mineralization of the
foot skeleton and no inflammatory signs occurred on
radiographs.
Methods
This observational prospective study was approved
2007 by the Review Board of Västra Götalands Regionen
(EPN D-number 499–07) with additional approval
2010 (T 762–10 ad 499–07). All the subjects provided
informed consent before participating in the study.
The study complies with the STROBE-statement for
observational studies [13]. We tested the following
hypotheses: (1) do plasma levels of IL-17 cytokines differ
between healthy subjects and diabetic patients with docu-
mented peripheral neuropathy (2) are plasma levels of IL-
17 cytokines in Charcot patients at presentation and
2 years postinclusion different from diabetic control
patients or healthy subjects and (3) do the levels of IL-17
cytokines change over time in Charcot patients and could
such changes be related to off-loading treatment.
Patient selection and treatment
Twenty-eight consecutive ambulatory men and women
admitted to Sahlgrenska University Hospital with clinical
signs of unilateral acute Charcot’s foot were included in
the study during 2009–2014. Two patients deceased
shortly after inclusion and were excluded. One patient
interrupted participation 19 months into the study after
being informed that radiographs showed finalized bone
healing, but did not object to data being processed in
the study. Inclusion of Charcot patients was based on
medical history, clinical examination and radiological
findings. Patients were included in the Charcot group if
they met the following criteria: (1) Type 1 or 2 diabetes
with duration of ≥ 1 year (2) peripheral bilateral neur-
opathy as defined below and (3) clinical signs of active
Charcot arthropathy with hot/reddened/swollen foot and
skin temperature in the affected foot of ≥ 2 °C higher
than in the contralateral foot. Within a day of inclusion,
Charcot patients received a non-weight bearing total
contact cast (TCC). The cast was repeatedly replaced as
required by changes in foot volume due to increased or
attenuated swelling. The non-weight-bearing protocol
was aided by crutches or wheel-chair and was continued
until the difference in skin temperature between the feet
was ≤ 1 °C and no signs of redness and swelling were
present for the past 30 days. TCC was then replaced by
orthosis for partial weight-bearing. Evaluation of skin
temperature and toe pressure continued until 2 years
postinclusion. When full weight-bearing was allowed,
the patient received prescribed accommodative shoes.
Bilateral foot radiograhs and magnetic resonance im-
aging (MRI) at inclusion and repeatedly during the
follow-up period were used to monitor dislocations,
fractures and soft tissue- or bone marrow edema. Exclu-
sion criteria were plantar ulcerations, documented his-
tory of trauma or surgery involving bone tissue during
the past year prior to inclusion, current immunosuppres-
sive therapy (steroids, cancer treatment) or medication
known to affect bone metabolism (e.g. bisphosphonates,
denosumab). A control group of twenty ambulatory
neuropathic patients with diabetes type 1 or 2 was in-
cluded at Frölunda Specialist Hospital during 2011 and
another group of twenty healthy subjects was included at
Sahlgrenska University Hospital/Mölndal during 2010.
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Both control groups lacked documented history of joint/
bone disease or bone trauma/surgery one year prior to in-
clusion and received no osteoporosis medication.
Skin sensitivity, skin temperature and toe pressure
Skin sensitivity was measured in Charcot patients and
diabetic control patients bilaterally at inclusion on 4
different locations of the foot using the Semmes-
Weinstein monofilament test [14]. The monofilament
(10 g) was pressed against the skin and the patient’s
ability or inability to feel the sensation upon buckling
of the monofilament was registered. Neuropathy was
present if three or more sites were insensate to the
monofilament. Skin temperature was measured bilat-
erally on the dorsal foot 5 cm distal of the ankle and
2 cm proximal of the mid toe. Toe blood pressure was
measured bilaterally using a specially designed cuff
[15]. Measurements of skin temperature and toe pres-
sure were performed at inclusion, 1 week, 2, 4, 6, 8, 12,
18 and 24 months thereafter.
Blood samples
Peripheral venous blood was collected for routine ana-
lyses (Hemoglobin, serum creatinine, CRP, SR and
HbA1c) and for cytokine analyses (pre-chilled EDTA
tubes immediately centrifuged at 3000xg for 10 min at
4 °C before being stored at −85 °C until analysis). Blood
was collected in the Charcot group at inclusion, 1 week,
2, 4, 6, 8, 12, 18 and 24 months after inclusion. In the
diabetic control group and the group of healthy subjects,
blood was sampled on a single occasion and the bio-
marker values obtained were used for comparisons with
Charcot patients both at inclusion and at 2 years post-
inclusion. Before analysis, samples were thawed on ice
before being mounted on assay plates and analyzed for
IL-17A, IL-17F, and IL-17E.
Determination of plasma biomarkers by ECL technology
The Sector Imager 2400 assay platform from MesoSca-
leDiagnostics (MSD, Gaithersburg, USA) was used for
biomarkers analysis (for details see www.mesoscale.com).
This electrogenerated chemiluminescence technique (ECL)
is a high-sensitivity assay platform with low detection limit
and wide dynamic range compared to colorimetric ELISAs
[16]. ECL uses plates with integrated screen-printed carbon
ink electrodes on the bottom of the wells (a working
electrode and a counter electrode generating an elec-
trical circuit) which act as both the capture phase for
solid phase immunoassays and the source of electro-
chemical energy for inducing chemiluminescence. The
capture antibody is attached to the carbon bottom
surface of the well and forms a sandwich with a bio-
tinylated detection antibody encapsulating the targeted
plasma protein. MSD Sulfo-TAG™ reagent is added and
forms a strong bond to the detection antibody by
biotin-streptavidin interactions. The ruthenium-based
tag is used in combination with an enhancer, tripropy-
lamine. The tag undergoes rapid redox-reaction that
emits light at 620 nm when excited by an electrical
impulse applied to the carbon electrode. Photon levels
from the Sulfo-TAG™ are imaged by a cooled (−28 °C)
CCD camera housed in the Sector Imager plate reader.
Only tag bound antibody-protein complexes in prox-
imity of the electrode are detected. Photon readings
from each plate are transferred to excel-based pivot
table and data for each cytokine is expressed against
known standards.
Quantitative measurements were done by use of a
matched pair of anti-human (ah) antibodies i.e. capture
antibody (CA) and biotinylated detection antibody
(DA). Standard curves were created by use of the corre-
sponding human recombinant proteins (hRP). Samples
were mounted on uncoated standard plates from MSD
(L15XA). IL-17A:CA/DA/hRP (Peprotech cat no.900-
K84), IL-17E:CA/DA/hRP (Peprotech cat no.900-K234)
and IL-17F:CA/DA/hRP (Peprotech cat no.900-K277).
Antibodies were optimized by checkerboard titrations
and subsequent control of standard curves. Plasma from
Charcot, diabetic controls and healthy subjects were
mounted on the same plate to minimize inter-group
variability. Inter-assay variations were <5 %.
Radiography
Radiographs of both feet were performed in supine
position with dorso-plantar, oblique and lateral pro-
jections as well as weight-bearing in frontal and lat-
eral projections. MRI was performed on a 1.5 T
Siemens Magnetom Symphony scanner with patients
supine and feet first into the gantry. All examinations
were performed by head-neck surface coil with feet in
flexed position. The feet were examined with 4 se-
quences each without intravenous contrast medium:
T1, T2, T2 3d and STIR sequences in sagittal, trans-
verse and coronary positions. Following administration of
intravenous contrast medium, transverse and sagittal pro-
jections were obtained by T-sequences. Radiographic
and MRI examinations were performed at a preset
schedule within a week after assigning the patient to
the study and 6, 12, 18 and 24 months after inclusion.
For anatomical classification of Charcot we used the
system described by Sanders and Frykberg with five
different patterns depending on the areas of the foot
affected [17], i.e. Pattern I: metatarsophalangeal and
interphalangeal joints; Pattern II: tarso-metatarsal joints;
Pattern III: naviculocuneiform, talonavicular and calca-
neocuboid joints; pattern IV: ankle and subtalar joints;
Pattern V: calcaneus (Table 1). A modified Eichenhotz
staging based on plain X-rays as described by Sella and
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Barrette [18], was used for disease characteristics and
comprises 5 stages: Stage 0 (warm, reddened, swollen foot
and normal radiographs), stage 1 (clinical findings and
radiographic cysts, erosions, localized osteopenia and
occasionally diastases), stage 2 (joint subluxation), stage 3
(dislocation and arch collapse), stage 4 (healed stage of
bony process) (Table 1). Inflammation in the soft-tissue
and bony structures of the foot (edema), were identified
by MRI and summarized in Table 2.
Statistical methods
Repeated measures ANOVA is also referred to as
within-subjects ANOVA or ANOVA for correlated sam-
ples and is a powerful tool when investigating changes in
mean scores over three or more time points as was done
in the Charcot group or when comparing three or more
groups of patients (Charcot, diabetic controls and
healthy). An important point with the current statistical
design is that the same populations are being measured
Table 1 Clinical and demographic data in Charcot patients, diabetic controls and healthy subjects
Charcot arthropathy Inclusion Charcot arthropathy
End of study
Diabetic controls Inclusion Diabetic controls +2Y Healthy subjects
(n = 26) (n = 26) (n = 20) (n = 20) (n = 20)
Age (median- range, years) 61 (42–87) 63 (42–87) 55 (20–94) 57 (20–94) 58 (24–78)
Gender (n)
Females 10 10 8 8 9
Males 16 16 12 12 11
Diabetes type 1/2 (n) 11/15 11/15 6/14 6/14 -
Diabetes duration (years) 25 ± 4 - 14 ± 6 - -
Debut foot symptoms
(weeks, median-range)
8.4 (1–24) - - - -
Systolic blood pressure
(mmHg)
149 ± 6 148 ± 6 127 ± 4 - 138 ± 4
Diastolic blood pressure
(mmHg)
80 ± 3 80 ± 3 76 ± 2 - 81 ± 3
Arterial toe pressure
(mmHg)
Charcot foot 114 ± 11 122 ± 8 115 ± 4 - -
Contralateral foot 129 ± 8 119 ± 7 114 ± 5 - -
Skin temperature (°C)
Charcot foot 31.3 ± 0.8a 29.7 ± 0.7 30,0 ± 0,4 - -
Contralateral foot 28.8 ± 0.9 29.3 ± 0.7 30,2 ± 0,4 - -
Pain at rest (n) 4 0 0 - -
Pain at weight bearing (n) 17 0 0 - -
Foot distorsion (n) 4 4 0 - 0
Total contact cast (months) - 7.7 ± 1.0 - - -
Charcot pattern
I/II/III/IV/V (n)
2/16/5/0/3 - - - -
Nephropathy/Cardiac
disease (n)
7/4 7/4 2/1 2/1 0/0
Hb (g/L) 127 ± 3 129 ± 3 136 ± 2 139 ± 3 143 ± 5
S-CRP (mg/L) 10.6 ± 3b,c 10.0 ± 2d,e 3.6 ± 0,8 3.8 ± 0,8 2.7 ± 0,7
SR (mm) 28.8 ± 6f,g 23 ± 5 11 ± 2 10 ± 2 6 ± 4
S-Kreatinin (μmol/L) 112 ± 19 101 ± 12 83 ± 8 89 ± 7 78 ± 5
HbA1c (mmol/mol) 60 ± 3 64 ± 2 58 ± 3 56 ± 2 -
HbA1c (%) 7.8 ± 0.3 7.4 ± 0.3 7.5 ± 0.2 7.3 ± 0.2 -
Mean ± SEM when not given differently. ap = 0.010 Charcot foot versus contralateral foot at inclusion. bp = 0.044 for Charcot at inclusion versus diabetic controls at
inclusion.cp = 0.012 for Charcot at inclusion versus healthy. dp = 0.038 Charcot end of study vs diabetic controls +2y. ep = 0.022 Charcot end of study vs healthy.
fp = 0.001 Charcot at inclusion versus diabetic controls at inclusion. gp < 0.001 for Charcot at inclusion versus healthy. All other differences are not significant.
Charcot pattern I-V on radiographs as described by Sanders and Frykberg (see ref: Papanas and Maltezos, 2013 [17])
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more than once on the same dependent variable, hence
the name “repeated measures analysis”. The one-way re-
peated measures ANOVA used in the current study re-
quire one dependent variable, often referred to as an
outcome variable, and one independent variable which
is the variable being treated and as a result affects the
dependent variable. The dependent variable needs to be
continuous (interval or ratio) and the independent vari-
able categorical and could be divided into categories,
also called levels. When we repeated measurements of
IL-17 in Charcot patients along the time axis, the inde-
pendent variable is time and each level is a specific time
point. The dependent variable is plasma IL-17. Thus, the
main aim of the study was to examine in Charcot foot
patients whether the independent variable, i.e. time from
inclusion (acute phase) to study termination (chronic
state), resulted in changes of the dependent variable,
plasma IL-17 and whether these changes occurred in
connection with TCC treatment. We were also inter-
ested knowing if there was a difference in IL-17 between
Charcot patients at inclusion and study termination rela-
tive the control groups. The independent variable consti-
tuted here of individuals in the 3 groups (three levels)
and the dependent variable was plasma IL-17.
Before analyzing the data by repeated measures
ANOVA we tested for a number of assumptions to be
met. The tested variables (biomarkers) were measured at
the continuous level over time and a comparison was
made between the 3 independent study groups for each
individual biomarker at inclusion and at 2 years postin-
clusion by means of one-way repeated measures
ANOVA followed by the Holm-Ŝidak test. When applic-
able, this model was used for comparisons between the
3 study groups for blood pressure, Hb, CRP, SR, S-
kreatinin (Table 1). This statistical model ensures that
the probability of incorrectly rejecting the null hypoth-
esis for any of the pairwise comparisons in the family
does not exceed alpha, thereby controlling the family-
wise error rate (FWE) and setting the alpha value ac-
cording to Ŝidak correction of Bonferroni inequality.
This stepwise method is generally more powerful than
the corresponding single-step procedures. The Holm-
Ŝidak test applies an accept/reject criterion on a sorted
set of null hypothesis, starting from the lower p-value
and going up to the acceptance of null hypothesis. For
each comparison, the alpha value is set according to
Ŝidak correction of Bonferroni inequality. The Ŝidak for-
mula is: Ŝidak corrected alpha = 1 - (1 - α)1/k where k (=3 in
our study) is the number of comparisons performed for
each individual biomarker. The Ŝidak procedure has
slightly more power than the Bonferroni procedure
when alpha = .05. A multiplicative model was assumed
more accurate for the current data and therefore the
logarithms of measurements have been used for the
comparisons. Comparisons between 2 datasets of indi-
vidual biomarkers within the Charcot group (e.g. inclu-
sion vs 4 months) were performed by Wilcoxon rank
sum test. Comparison of HbA1c between the Charcot
and diabetic control groups was done by Mann-
Whitney U test (Table 1).
As plasma IL-17 cytokines have not been previously
reported in Charcot patients, we were unable to assume
means and standard deviations as known quantities and
could therefore not conduct an a priori power analysis
using information from studies in the literature. A post hoc
analysis of sample size for ANOVA based on obtained mea-
surements of plasma IL-17 was conducted yielding a sam-
ple size of 17 when comparing 3 groups with a difference
in means (20), mean SD (90), power (0.8) and alpha (0.05).
Results
IL-17A
Plasma IL-17A (pg/ml) did not differ significantly be-
tween Charcot patients, diabetic controls or healthy sub-
jects at inclusion (p = 0.77) or at 2 years postinclusion
(p = 0.16) (Fig. 1a). Plasma IL-17A in Charcot patients
had not changed significantly at 2 years versus value at
inclusion (p = 0.33) (Fig. 1a). IL-17A in Charcot patients
was significantly higher at 4 months versus Charcot at
presentation (p = 0.002) (Fig. 1b).
IL-17E
Plasma IL-17E at inclusion did not differ significantly
between Charcot, diabetic controls and healthy subjects
(p = 0.073) (Fig. 2a). Two years postinclusion, IL-17E
was significantly higher in Charcot patients versus dia-
betic controls (p = 0.021) and versus healthy subjects
(p = 0.002) but did not differ significantly between
diabetic controls and healthy (p = 0.32) (Fig. 2a).
Plasma IL-17E in Charcot patients at 2 years had not
changed significantly from value at inclusion (p = 0.23)
Table 2 Staging of radiographic changes in the Charcot
arthropathy foot as described by Sella and Barrette (1999)
[18] based on weight-bearing radiographic examinations of
the diseased foot and inflammation/bone edema on MRI.
Numbers in table are number of patients
Radiographs Inclusion 1 W 6 M 12 M 18 M 24 M
Stage 0 4 3 0 0 0 0
Stage 1 3 3 2 0 0 0
Stage 2 9 9 9 6 4 0
Stage 3 10 10 10 5 5 0
Stage 4 0 1 5 15 17 25
MRI Inclusion 1 W 6 M 12 M 18 M 24 M
Soft tissue edema 22 22 18 14 7 0
Bone marrow edema 18 18 15 13 5 0
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(Fig. 2a). IL-17E in Charcot patients was significantly
higher at 4 months versus Charcot at presentation
(p < 0.001) (Fig. 2b).
IL-17F
Plasma IL-17F at inclusion was significantly lower in
Charcot patients relative diabetic controls (p = 0.024)
and relative healthy subjects (p = 0.047), whereas
difference between diabetic controls and healthy was
not significant (p = 0.69) (Fig. 3a). Differences between
Charcot patients, diabetic controls and healthy subjects
at 2 years postinclusion were not significant (p = 0.95)
(Fig. 3a). Plasma IL-17F in Charcot patients had in-
creased significantly at 2 years relative value at inclusion
(p = 0.003) (Fig. 3a). IL-17F in Charcot patients was not
significantly higher at 4 months versus inclusion value
(p = 0.57) (Fig. 3b).
Radiographic data
The radiographic data are presented in table 2. One pa-
tient lacked data at 24 months due to interrupted par-
ticipation. All study patients had reached complete
mineralization on radiographs and no signs of inflamma-
tion on MRI at 2 years postinclusion.
Discussion
Our results showed no significant differences between
neuropathic diabetic control patients and healthy subjects
a
b
Fig. 1 Plasma levels of IL-17A (pg/ml) in Charcot patients (n = 26), diabetes control patients (n = 20) and healthy donors (n = 20). IL-17A was not
significantly different between Charcot patients, diabetic control patients and healthy subjects at inclusion into the study (p = 0.77) or at 2 years
(p = 0.16). Plasma IL-17A in Charcot patients had not changed significantly at 2 years relative value at inclusion (p = 0.33) (1a). IL-17A in Charcot
patients had increased significantly at 4 months relative value at inclusion (p = 0.002) (1b). Mean ± SEM
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for IL-17A (Fig. 1a). These results are in line with previous
studies showing no significant difference in serum levels of
IL-17A between type 2 diabetic patients and healthy sub-
jects [19–21] whereas one study showed significantly lower
serum level of IL-17A in neuropathic type 2 diabetic
patients versus healthy subjects [22]. We are however not
aware of previous studies reporting on the systemic levels
of IL-17E and IL-17F in diabetic patients except for one
study reporting on IL-17F in infected diabetic patients [23].
Following an immunological insult, e.g. tissue trauma,
naïve T cells differentiate to mature pathogenic Th17 cells
and release IL-17A, an early initiator of inflammation,
which stimulates other immune cells to release proinflam-
matory cytokines, such as IL-1β, and chemokines thereby
creating a positive autocrine feedback loop amplifying the
inflammatory reaction and promoting osteoclastogenesis
[24–26]. The current results showing IL-17A in Charcot
patients not to differ significantly from diabetic controls at
inclusion (Fig. 1) suggest that this positive feedback loop
may have been inhibited [26]. In contrast to IL-17A,
plasma IL-17F was significantly lower in Charcot versus
diabetic controls and healthy subjects (Fig. 3). The latter
finding was surprising considering the strong structural
resemblance between IL-17A and IL-17F and that both
a
b
Fig. 2 Plasma levels of IL-IL-17E (pg/ml) in Charcot patients (n = 26), diabetes control patients (n = 20) and healthy donors (n = 20). IL-17E was not
significantly different between Charcot patients, diabetic control patients and healthy subjects at inclusion into the study (p = 0.73) (2a). At 2 years,
IL-17E was significantly higher for Charcot patients relative diabetic controls (p = 0.021) and relative healthy (p = 0.002) but not between diabetic
controls and healthy (p = 0.32). Plasma IL-17E in Charcot patients had not changed significantly at 2 years relative value at inclusion (p = 0.23) (2a).
IL-17E in Charcot patients had increased significantly at 4 months relative value at inclusion (p < 0.001) (2b). Mean ± SEM
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are regulated by similar molecular mechanisms [11] which
should make them function redundantly in promoting in-
flammation and bone erosion. Although both IL-17A and
IL-17F induce neutrophil recruitment, recent data have
shown the two cytokines to have differential effects and
potencies and even to oppose each other [11, 12]. While
T-helper cells are important promoters of osteolysis, they
are also a source of anti-inflammatory mediators, such as
IL-4, IL-10 and IL-13, being important inhibitors of osteo-
clastic activity. In a study by Yang et al. [11], IL-17A
deficiency was shown to greatly reduce anti-inflammatory
Th2 cytokines (IL-4, IL-5 and IL-13), whereas IL-17F defi-
ciency contrarily enhanced these anti-inflammatory cyto-
kines known to negatively regulate IL-17A [27]. This
seemingly paradoxical effect by the two cytokines could
help explain our findings at the time of Charcot diagnosis
when the patient had exerted full weight bearing on the dis-
eased foot. The suppression of IL-17F could thus serve as a
protective measure by containing the IL-17A-induced pro-
duction of osteoclastogenic pro-inflammatory cytokines
a
b
Fig. 3 Plasma levels of IL-17F (pg/ml) in Charcot patients (n = 26), diabetes control patients (n = 20) and healthy donors (n = 20). Plasma IL-17F at
start of study was significantly lower in Charcot patients versus diabetic controls (p = 0.024) and healthy subjects (p = 0.047) but not between diabetic
controls and healthy (p = 0.69). IL-17F was not significantly different between Charcot patients, diabetic control patients and healthy subjects at 2 years
(p = 0.95) (3a). IL-17F in Charcot patients was significantly higher at 2 years versus inclusion value (p = 0.003) (3a) but not at 4 months versus inclusion
value (3b) (p = 0.57). Mean ± SEM
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and at the same time increasing the levels of anti-
inflammatory cytokines.
Within a week after the start of offloading treatment,
systemic levels of IL-17A started to increase more than
4-fould peaking at 4 months before gradually receding
towards the end of the study (Fig. 1). This increase ap-
pears paradoxical in view of IL-17A being a strong pro-
moter of osteoclastogenesis [24–26] and in view of
radiological data showing offloading treatment to set-off
the process of bone mineralization (Table 2). Similar to
IL-17A, levels of IL-17E (IL-25) started to increase
shortly after offloading and reached a peak after 2 month
before gradually returning towards inclusion levels
(Fig. 2). The striking similarity in the response by IL-
17A and IL-17E came as a surprise considering that the
latter cytokine belongs to a different subset of T-helper
cells (Th2) than IL-17A (Th17). The main features of
IL-17E, besides eosinophilia, is to inhibit the produc-
tion of pro-inflammatory cytokines, such as TNF-α and
IL-17A, and at the same time shift immune responses
towards the Th2 phenotype and thereby increase the
production of anti-inflammatory cytokines, such as IL-
4, Il-5 and IL-13 [28]. A recent study in collagen-
induced experimental arthritis in mice knee joints [29]
could shed some light on this parallel increase of the
two opposing cytokines. The authors showed that as
IL-17E increased, the production of IL-17A increased at
first before decreasing and suggested that a negative regu-
lation exists between the two cytokines with IL-17E slow-
ing down the arthritic inflammation by suppressing IL-
17A and by increasing the anti-inflammatory IL-4 [29]. A
similar pattern was seen in the current study showing IL-
17E to reach its peak at 2 months followed by IL-17A
peaking at 4 months before both cytokines retreated. This
could suggest that IL-17E has a beneficial role in Charcot
patients by increasing the expression of Th2-derived anti-
inflammatory cytokines [28] and at the same time
counter-balancing the negative effects of IL-17A on the
skeleton [29]. In a recent study investigating the role
of the potent bone regulating Wnt/β-catenin pathway
in Charcot arthropathy patients [30], we were able to
show that 4 months after the start of offloading treat-
ment, a significant increase occurred in systemic
levels of the Wnt antagonist, dickkopf-1 (Dkk-1), and
the Wnt agonist, Wnt-1, both being part of bone remodel-
ing [31, 32]. The present findings showing that the increase
in IL-17A and IL-17E following offloading coincided with
Dkk-1 and Wnt-1, could suggest that the two systems
interact in the control of bone remodeling activity at
the early stage of bone repair in Charcot patients. A
positive inter-regulatory link between the two systems
was recently confirmed in a patient study on fragility
fractures showing that a decreased expression of scler-
ostin, an endogenous inhibitor of the Wnt/β-catenin
pathway, was paralleled by a decrease in proinflammatory
cytokine expression [33] \thus lending support to a recent
suggestion made by Daoussis et al. [34, 35] that mediators
of these two systems are critical in joint remodeling and
may be appropriate targets in the treatment of bone and
joint abnormalities.
As opposed to IL-17A, which did not differ between
the three groups at 2 years, IL-17E was significantly
higher in Charcot patients versus diabetic controls and
healthy (Fig. 2). The latter findings, which signify a con-
tinued anti-osteoclatogenic activity in the chronic phase
of the disease, may appear surprising considering that
Charcot patients showed complete mineralization of the
damaged skeleton on radiographs and no presence of ac-
tive inflammation on MRI (Table 2). However, given the
fact that chronic Charcot often is characterized by arch
collapse and other bone deformities leading to unnatural
high pressure on areas of the foot, there could be a con-
tinued need for bone repair and remodeling after pa-
tients had resumed full weight-bearing [36]. Thus, an
elevation of a cytokine being part of the mechanisms
combating osteoclastogenesis may constitute part of a
defensive mechanism to preserve the bone in the after-
math of Charcot arthropathy.
Contrary to the rapid increase of systemic IL-17A and
IL-17E following offloading treatment, the increase of IL-
17F was more gradual and extended over the entire obser-
vation period before reaching a level similar to diabetic
and healthy controls at 2 years postinclusion (Fig. 3). The
specific role of IL-17F on bone has only recently begun to
emerge showing this pro-inflammatory cytokine to enable
osteoblast maturation and activation which allows bone
synthesis to occur as part of its osteoinductive role [37].
Our results showing IL-17F to be suppressed in patients
exerting full weight-bearing on the insensate foot at Char-
cot presentation could suggest that the osteoblast promot-
ing activity of IL-17F was inhibited by excessive motion at
the site of injury due to shear loading and that it was grad-
ually restored after the fractured foot had been stabilized
by total cast and offloading treatment thereby improving
the biomechanical environment for repair (Fig. 2).
Conclusions
While there is some evidence in support of Th1/Th2 cy-
tokines in the pathophysiology of Charcot arthropathy,
this is the first study to support a role for the IL-17 fam-
ily of proinflammatory cytokines in the pathophysiology
of Charcot arthropathy patients. With increased under-
standing of the bone regulatory mechanisms controlled
by members of the IL-17 family, our results showing sys-
temic increase of all three cytokines suggest that they
take part in the bone repair and remodeling activity dur-
ing the recovery phase of Charcot as supported by stud-
ies showing direct T-cell involvement in the control of
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fracture healing [38]. Moreover, the increase of IL-17A
and IL-17E within a week after initiation of offloading
treatment suggest that activation of these cytokines could
have been triggered by fixation and immobilization of the
foot as fracture stability is a prerequisite for normal bone
repair [38]. Better understanding of the molecular mecha-
nisms triggering and regulating bone repair in of Charcot
arthropathy is of particular relevance when considering
recent development in the area of drugs targeting the Wnt
and IL-17 signaling pathways which hold great promise as
a future therapeutic approach to treat common bone dis-
orders [25, 39].
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